For research use only
| Cat No. | ABC-TC252S |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphocyte-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Product Code | Nalm-6; NALM 6; Nalm 6; NALM6; Nalm6; NALM-6-M1 |
NALM-6 cells are B-ALL lymphoblasts with t(5;12) translocation, expressing B-cell markers and forming systemic metastases in immunocompromised mice.
NALM-6 cell line was established from peripheral blood cultures of a 19-year-old male patient during relapse of acute lymphoblastic leukemia (ALL). While initially diagnosed as non-T, non-B ALL, the relapsed blasts exhibited a unique membrane phenotype expressing surface immunoglobulin (SmIg lambda and mu chains), Ia-like B-cell antigen, and common ALL antigen (cALL), differing from the original presentation. Among the cultured cells, eight leukemia lines (NALM 6-13) and two normal B-cell lines were obtained. Despite sharing cytogenetic markers (5q- and 12p⁺) and monoclonal SmIg expression, the leukemia lines showed membrane phenotype variations, suggesting limited intraclonal differentiation within the leukemic population. The cells grow in suspension as small, round lymphoblasts expressing B‑lineage markers CD10, CD19, cytoplasmic CD79a and HLA‑DR. NALM‑6 maintains a stable, near‑diploid karyotype (43–47 chromosomes) with a characteristic t(5;12)(q33;p13) translocation. In vivo, NALM‑6 forms systemic metastases, including bone marrow, spleen, and liver when implanted into immunodeficient mice. This cell line provides a valuable model for studying B-cell-associated ALL with phenotypic plasticity.
| Product Code | Nalm-6; NALM 6; Nalm 6; NALM6; Nalm6; NALM-6-M1 |
| Species | Human |
| Cat.No | ABC-TC252S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
NALM-6 cell line is widely used as a model for studying the biology and treatment of acute lymphoblastic leukemia. It offers an excellent platform for investigating B-cell development, oncogenic signaling, and therapeutic resistance. NALM-6 is particularly useful in examining the potential accumulation of oxidative clustered DNA lesions in leukemia cells following radiation exposure, simulating conditions seen in radiotherapy. These studies help elucidate damage responses in leukemia and aid to design novel therapeutic approaches, advancing both basic research and translational applications in hematologic malignancies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
NALM-6 cell line were originally isolated from peripheral blood of a patient with acute lymphoblastic leukemia (ALL) in relapse.
The seeding density is 2 × 10^5 cells/mL, it is recommended to keep the cell concentration within the range of 1 × 10^5 to 1 × 10^6 cells/mL for optimal growth.
The utility of Nalm-6 cells extends to studying the efficacy of therapeutic targets and existing drug resistance mechanisms, provides a unique way for researching the genomic landscape of the disease, including genomic instability and DNA repair mechanisms. It can also be helpful for studying the complex nature of acute leukemia.
The doubling time of NALM-6 cell line is around 35 to 40 hours. It could be different due to the batches.
